Success Metrics

Clinical Success Rate

25.0%

Based on 1 completed trials

Completion Rate

25%(1/4)

Active Trials

0(0%)

Results Posted

200%(2 trials)

Terminated

3(75%)

Phase Distribution

Ph phase_1

50%

Ph phase_2

25%

Ph phase_3

25%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution4 total trials

Phase 1Safety & dosage

2(50.0%)

Phase 2Efficacy & side effects

1(25.0%)

Phase 3Large-scale testing

1(25.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

25.0%

1 of 4 finished

Non-Completion Rate

75.0%

3 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(1)

Terminated(3)

Detailed Status

Terminated3

Completed1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

25.0%

Most Advanced

Phase 3

Trials by Phase

Phase 12 (50.0%)

Phase 21 (25.0%)

Phase 31 (25.0%)

Trials by Status

completed125%

terminated375%

Recent Activity

0 active trials

Showing 4 of 4

terminatedphase_3

SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small-cell Lung Cancer Patients

NCT04154956

completedphase_1

Evaluation of SAR408701 in Japanese Patients With Advanced Malignant Solid Tumors

NCT03324113

terminatedphase_2

Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab or Ramucirumab and Pembrolizumab in Pretreated Patients With NSQ NSCLC (CARMEN-LC04)

NCT04394624

terminatedphase_1

Evaluation of SAR408701 in Patients With Advanced Solid Tumors

NCT02187848

Clinical Trials (4)

Showing 4 of 4 trials

NCT04154956Phase 3

SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small-cell Lung Cancer Patients

Terminated

NCT03324113Phase 1

Evaluation of SAR408701 in Japanese Patients With Advanced Malignant Solid Tumors

Completed

NCT04394624Phase 2

Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab or Ramucirumab and Pembrolizumab in Pretreated Patients With NSQ NSCLC (CARMEN-LC04)

Terminated

NCT02187848Phase 1

Evaluation of SAR408701 in Patients With Advanced Solid Tumors

Terminated

All 4 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 4